Allaert F-A, Mosnier M
Epidemiology and Biostatistics Department, McGill University, 845, rue Sherbrooke Ouest, Montreal, Québec, Canada, H3A 2T5.
Ann Cardiol Angeiol (Paris). 2008 Feb;57(1):22-8. doi: 10.1016/j.ancard.2007.08.014. Epub 2007 Nov 12.
To assess in a daily practice survey one-year survival in a cohort of patients with heart failure (HF) according to their clinical profiles and the way they were managed by cardiologists.
A prospective observational survey was conducted in 1941 patients with HF followed up for one year. Results show high rates of prescription for ACE inhibitors, indicating that cardiologists take into account international recommendations. ACE inhibitors are prescribed at dosage levels approaching those recommended by the guidelines. However, beta-blocker prescription still shows a significant deficit and the prescribed doses are much lower than those currently recommended. The multifactorial modeling analysis showed that global heart failure (P=0.004), advanced NYHA class (P<0.001), renal failure (P<0.001) were predictive of poor outcome whereas an increased survival likelihood was observed in patients given ACE-inhibitor/beta-blocker combination compared with beta-blocker alone or ACE-inhibitor alone.
The results from this study should enhance the prescription of ACE inhibitors and beta-blockers at effective doses in compliance with the guidelines. They also suggest that a synergic positive effect of the combination of these two therapeutic classes is observed in real life situations.
在一项日常实践调查中,根据心力衰竭(HF)患者的临床特征以及心脏病专家的管理方式,评估该队列患者的一年生存率。
对1941例HF患者进行了为期一年的前瞻性观察调查。结果显示,ACE抑制剂的处方率很高,表明心脏病专家考虑到了国际建议。ACE抑制剂的处方剂量接近指南推荐的剂量。然而,β受体阻滞剂的处方率仍存在显著不足,且处方剂量远低于目前推荐的剂量。多因素模型分析表明,全心衰(P = 0.004)、纽约心脏协会(NYHA)分级晚期(P < 0.001)、肾衰竭(P < 0.001)是预后不良的预测因素,而与单独使用β受体阻滞剂或ACE抑制剂相比,接受ACE抑制剂/β受体阻滞剂联合治疗的患者生存可能性增加。
本研究结果应能提高符合指南的有效剂量的ACE抑制剂和β受体阻滞剂的处方率。它们还表明,在现实生活中观察到这两类治疗药物联合使用具有协同积极作用。